This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Takes Welcome Steps To Help More Smokers Quit

WASHINGTON, April 1, 2013 /PRNewswire-USNewswire/ -- The following is a statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids:


The Food and Drug Administration (FDA) today has taken important steps to help more smokers quit by revising the required labeling of over-the-counter nicotine replacement therapies (NRTs) to eliminate language that could discourage effective use of these products.  Specifically, manufacturers will no longer have to include labeling statements that warn against any smoking or other tobacco use while using NRTs or use of more than one NRT product, and that strictly limits the duration of treatment with these medications.

These labeling changes recognize that cigarette smoking is extremely addictive, and most smokers make multiple attempts to quit before they succeed.  The changes will help more smokers to safely and effectively use NRT products to quit smoking.  An FDA consumer update specifically states, "If you are using an OTC NRT while trying to quit smoking but slip up and have a cigarette, you should not stop using the NRT.  You should keep using the OTC NRT and keep trying to quit."

Current labeling discourages smokers trying to quit from continuing to use these therapies when they relapse.  In addition, many smokers are unable to quit within the length of time approved for these products. These restrictions may be preventing smokers from using NRT products – including nicotine gum, patches and lozenges – in ways that could significantly increase the number who quit successfully.

According to the U.S. Public Health Service's Clinical Practice Guideline, Treating Tobacco Use and Dependence, long-term NRT use is effective.  These guidelines recognize that continued use of such medicines is preferable to a return to smoking because they do not contain the many non-nicotine toxins that are found in cigarettes.  The clinical practice guidelines also discuss a number of studies that show some patients benefit from the combined use of smoking cessation products, including different NRT products.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs